
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie demonstrates a robust growth trajectory, with management projecting a high single-digit sales compound annual growth rate (CAGR) from 2024 to 2029, supported by strong sales expectations for Skyrizi and Rinvoq, which are anticipated to surpass $20 billion and $11 billion respectively by 2027. The company reported fourth-quarter 2024 sales of $15.1 billion, exceeding expectations primarily due to significant contributions from its immunology portfolio, which positions AbbVie favorably for continued growth in the near term. Additionally, the initial EPS guidance for 2025 is between $12.12 and $12.32, indicating solid profitability prospects as the company navigates its evolving product landscape.
Bears say
AbbVie's negative outlook is driven by several key risks, including disappointing commercial performance from crucial products like Skyrizi, Rinvoq, and Botox, which are essential for maintaining revenue stability. The anticipated market erosion of Humira due to the entry of biosimilars and slower than expected growth in key areas, such as inflammatory bowel disease, further complicate long-term revenue expectations. Additionally, macroeconomic challenges, particularly affecting the aesthetics sector, combined with potential pipeline setbacks, present significant headwinds that could hinder AbbVie's overall financial performance.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares